- Home
- OLP vs PLRX Comparison
OLP vs PLRX Comparison
Compare OLP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | PLRX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OLP | PLRX |
|---|---|---|
| Price | $20.06 | $1.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 106.9K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $97,423,000.00 | N/A |
| Revenue This Year | $7.95 | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | ★ 9.29 | N/A |
| 52 Week Low | $19.62 | $1.10 |
| 52 Week High | $28.36 | $14.26 |
Technical Indicators
Market Signals| Indicator | OLP | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 37.73 |
| Support Level | $19.86 | $1.20 |
| Resistance Level | $21.66 | $1.27 |
| Average True Range (ATR) | 0.36 | 0.07 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 13.60 | 28.57 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.